Clinical outcomes of <i>ALK</i> + non-small cell lung cancer in Denmark-Reference-Cited by-同舟云学术

Clinical outcomes of ALK + non-small cell lung cancer in Denmark

Published:2023-10-10 Issue:12 Volume:62 Page:1775-1783
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Hansen Karin Holmskov¹,Johansen Jakob Sidenius²,Urbanska Edyta Maria³,Meldgaard Peter⁴,Hjorth-Hansen Peter⁵,Kristiansen Charlotte⁶,Stelmach Miroslaw⁷,Santoni-Rugiu Eric⁸,Ulhøi Maiken Parm⁴,Dydensborg Anders Bondo⁹,Dünweber Christina⁹,Andersen Jon Lykkegaard²

Affiliation:

1. Department of Oncology, Odense University Hospital, Odense, Denmark

2. Department of Oncology, Herlev and Gentofte University Hospital, Copenhagen, Denmark

3. Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

4. Department of Oncology, Aarhus University Hospital, Aarhus, Denmark

5. Department of Oncology, Aalborg University Hospital, Aalborg, Denmark

6. Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark

7. Department of Oncology, Næstved Hospital, Næstved, Denmark

8. Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

9. Takeda Pharma A/S, Copenhagen, Denmark

Funder

Takeda Pharma A/S, a subsidiary of Takeda Pharmaceuticals Inc

Publisher

Medical Journals Sweden AB

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2023.2263153

Reference20 articles.

1. ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer

2. EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer

3. TheEML4-ALKfusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-typeEGFRandKRAS

4. The Landscape of ALK-Rearranged Non-Small Cell Lung Cancer: A Comprehensive Review of Clinicopathologic, Genomic Characteristics, and Therapeutic Perspectives

5. Is long-term survival possible for patients with stage IV ALK+ non-small cell lung cancer?

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ceritinib as a long-term disease control: Clinical observation;Meditsinskiy sovet = Medical Council;2024-07-24

2. Lung cancer patients with anaplastic lymphoma kinase rearrangement lose affiliation with labor market at diagnosis;Lung Cancer Management;2024-03-13